DE20102817U1 - Lozenges and chewing pills with cyclodextrin - Google Patents

Lozenges and chewing pills with cyclodextrin

Info

Publication number
DE20102817U1
DE20102817U1 DE20102817U DE20102817U DE20102817U1 DE 20102817 U1 DE20102817 U1 DE 20102817U1 DE 20102817 U DE20102817 U DE 20102817U DE 20102817 U DE20102817 U DE 20102817U DE 20102817 U1 DE20102817 U1 DE 20102817U1
Authority
DE
Germany
Prior art keywords
chewing
extract
cyclodextrin
sucking
pastilles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20102817U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bolder Arzneimittel GmbH
Original Assignee
Bolder Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolder Arzneimittel GmbH filed Critical Bolder Arzneimittel GmbH
Priority to DE20102817U priority Critical patent/DE20102817U1/en
Publication of DE20102817U1 publication Critical patent/DE20102817U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically

Claims (7)

1. Lutsch- und Kaupastillen auf der Basis wasserlöslicher oder in wässrigen Systemen Gel-bildender Hydrokolloide mit einem Arzneimittelwirkstoff und einem Cyclodextrin neben gegebenenfalls weiteren Hilfs- und Zusatzstoffen.1. Lozenges and chewing pastilles based on water-soluble or in aqueous systems of gel-forming hydrocolloids with a Active pharmaceutical ingredient and a cyclodextrin in addition optionally other auxiliaries and additives. 2. Lutsch- und Kaupastillen nach Anspruch 1, dadurch gekennzeichnet, dass sie 10 bis 60 Gew.-% Arabisches Gummi und/oder 5 bis 30 Gew.% Gelatine, 20 bis 75 Gew.% Arzneimittelwirkstoff und insbesondere 5 bis 40 Gew.% Cyclodextrin, jeweils bezogen auf die Gesamtmasse der Pastillen, enthalten.2. sucking and chewing pastilles according to claim 1, characterized characterized as having 10 to 60% by weight arabic gum and / or 5 to 30% by weight gelatin, 20 to 75% by weight Active pharmaceutical ingredient and in particular 5 to 40% by weight Cyclodextrin, each based on the total mass of Pastilles. 3. Lutsch- und Kaupastillen nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass der bittere Arzneimittelwirkstoff chemisch definiert ist.3. sucking and chewing pastilles according to claim 1 or 2, characterized characterized that the bitter drug substance chemically is defined. 4. Lutsch- und Kaupastillen nach Anspruch 3, dadurch gekennzeichnet, dass der Arzneimittelwirkstoff Dextromethorphan, Natriumdibunat, Ambroxol, Clobutanol, Dimenhydrinat, Tramadolhydrochlorid, Coffein, Codein, Paracetamol und/oder Theophyllin umfasst.4. sucking and chewing pastilles according to claim 3, characterized characterized that the drug ingredient Dextromethorphan, sodium dibunate, ambroxol, clobutanol, Dimenhydrinate, tramadol hydrochloride, caffeine, codeine, Paracetamol and / or theophylline includes. 5. Lutsch- und Kaupastillen nach Anspruch 3, dadurch gekennzeichnet, dass der Arzneimittelwirkstoff ausgewählt ist aus Pflanzenextrakten mit bitteren Inhaltsstoffen, insbesondere Thymian-Extrakt, Ingwer-Extrakt, Grüntee-Extrakt, Primel- Extrakt, Johanniskraut-Extrakt, Teufelskralle-Extrakt, Artischocken-Extrakt, Rosskastanien-Extrakt, Ringelblumen- Extrakt, Etherische Öle, wie Pfefferminzöl, Eucalyptusöl, Myrtol, Anisöl, Fenchelöl, Schwarzer Kümmelöl und/oder Salbeiöl.5. sucking and chewing pastilles according to claim 3, characterized characterized that the drug ingredient is selected from plant extracts with bitter ingredients, in particular Thyme extract, ginger extract, green tea extract, primrose Extract, St. John's wort extract, devil's claw extract, Artichoke Extract, Horse Chestnut Extract, Marigold  Extract, essential oils such as peppermint oil, eucalyptus oil, myrtol, Anise oil, fennel oil, black caraway oil and / or sage oil. 6. Lutsch- und Kaupastillen nach Anspruch 1, dadurch gekennzeichnet, dass die Hilfs- und Zusatzstoffe ausgewählt sind aus Saccharose, Glukosesirup, Zuckeralkoholen, Isomalt, Stärke, Süßstoffen, Wachsen und/oder Paraffinöl.6. sucking and chewing pastilles according to claim 1, characterized characterized that the auxiliaries and additives selected are made from sucrose, glucose syrup, sugar alcohols, isomalt, Starch, sweeteners, waxes and / or paraffin oil. 7. Lutsch- und Kaupastillen nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass das Cyclodextrin ausgewählt ist aus Beta-Cyclodextrindextrin, I-Alpha-Cyclodextrin, I- Hydroxypropyl-betacyclodextrin und/oder Dimethyl-beta­ cyclodextrin.7. sucking and chewing pastilles according to one of claims 1 to 6, characterized in that the cyclodextrin is selected from beta-cyclodextrindextrin, I-alpha-cyclodextrin, I- Hydroxypropyl beta cyclodextrin and / or dimethyl beta cyclodextrin.
DE20102817U 2000-02-23 2001-02-17 Lozenges and chewing pills with cyclodextrin Expired - Lifetime DE20102817U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE20102817U DE20102817U1 (en) 2000-02-23 2001-02-17 Lozenges and chewing pills with cyclodextrin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10008336 2000-02-23
DE20102817U DE20102817U1 (en) 2000-02-23 2001-02-17 Lozenges and chewing pills with cyclodextrin

Publications (1)

Publication Number Publication Date
DE20102817U1 true DE20102817U1 (en) 2001-06-07

Family

ID=7632033

Family Applications (1)

Application Number Title Priority Date Filing Date
DE20102817U Expired - Lifetime DE20102817U1 (en) 2000-02-23 2001-02-17 Lozenges and chewing pills with cyclodextrin

Country Status (1)

Country Link
DE (1) DE20102817U1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10208313A1 (en) * 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol for the treatment of painful conditions in the mouth and throat
EP1550438A2 (en) * 2003-12-16 2005-07-06 Advance Holdings Limited Method for preparing a medicated candy containing ambroxol and the thus obtained candy
EP1553925A1 (en) * 2002-09-16 2005-07-20 SmithKline Beecham Corporation Modified release oral dosage form
WO2011058336A3 (en) * 2009-11-16 2012-01-12 Aston University Tablet comprising gum arabic
DE102012221900A1 (en) 2012-11-29 2014-06-05 2LUTION GmbH Solid solution of caffeine and its derivative in a formulation material, useful as a dietary supplement, food or beverage or as a cosmetic agent, comprise a carrier material and solvent comprising glycerol and propylene glycol

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10208313A1 (en) * 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol for the treatment of painful conditions in the mouth and throat
EP1553925A1 (en) * 2002-09-16 2005-07-20 SmithKline Beecham Corporation Modified release oral dosage form
EP1553925A4 (en) * 2002-09-16 2012-09-05 Glaxosmithkline Llc Modified release oral dosage form
EP1550438A2 (en) * 2003-12-16 2005-07-06 Advance Holdings Limited Method for preparing a medicated candy containing ambroxol and the thus obtained candy
EP1550438A3 (en) * 2003-12-16 2005-08-10 Advance Holdings Limited Method for preparing a medicated candy containing ambroxol and the thus obtained candy
WO2011058336A3 (en) * 2009-11-16 2012-01-12 Aston University Tablet comprising gum arabic
DE102012221900A1 (en) 2012-11-29 2014-06-05 2LUTION GmbH Solid solution of caffeine and its derivative in a formulation material, useful as a dietary supplement, food or beverage or as a cosmetic agent, comprise a carrier material and solvent comprising glycerol and propylene glycol

Similar Documents

Publication Publication Date Title
DE20102817U1 (en) Lozenges and chewing pills with cyclodextrin
DE3527852A1 (en) PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
DE1179669B (en) Method of making a cough suppressant
CN101237781A (en) Confectionery products for the treatment of dry mouth
DE2610020A1 (en) PHARMACEUTICAL COMPOSITION
DE2252637C3 (en) Use of 1,3-glycerin dieters
WO2008125239A2 (en) Dry extracts of pelargonium sidoides and pelargonium reniforme
SK15362003A3 (en) Breath protection microcapsules
EP1037647B2 (en) Medicinal plant dry extracts
EP0073428A2 (en) Medicinal preparations for glycoside-hydrolase inhibitors
Willis et al. Vampyrodes caraccioli
DE3528168C1 (en) Additive for cosmetic preparations
DE2112430B2 (en) Process for the production of a medicament containing active ingredients and coronary and peripheral vasodilatory properties from plant extracts
WO2000037044A1 (en) Soft and chewy cough and cold relief composition
WO2011147992A1 (en) Thyme / primrose or ivy for treating chronic obstructive pulmonary diseases (copd)
DE69932077T2 (en) CHEESE WITH INCREASED TASTE LEAVING USING AN ALGINATE MATERIAL
EP1007007A1 (en) Ascorbic acid-based formulation with improved colour stability
DE1692463C3 (en) Livestock and poultry growth and development promoting agent containing cysteine and homocysteine
Luttges et al. Postinjury changes in the biomechanics of nerves and roots in mice
DE1492885C3 (en) Complementary feed for animals
Roersch Pluchea carolinensis (Jacq.) G. Don
Best et al. Sciurus yucatanensis
DE202021106726U1 (en) Polyherbal composition
Shurcliffe et al. Territory in the Australian Magpie (Gymnorhina tibicen), an analysis of its size and change
DE2737735C3 (en) Medicines containing pirbutero and hydroxyzine

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20010712

R150 Term of protection extended to 6 years

Effective date: 20040518

R151 Term of protection extended to 8 years

Effective date: 20070514

R158 Lapse of ip right after 8 years

Effective date: 20090901